We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
11.50 | 0.70% | 1,651.00 | 1,651.00 | 1,652.00 | 1,656.00 | 1,637.00 | 1,650.50 | 4,661,376 | 16:35:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.80 | 68.01B |
TIDMGSK
RNS Number : 0192D
GlaxoSmithKline PLC
21 April 2017
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Ms E Walmsley === ======================== ================================================ b) Position/status Chief Executive Officer === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.47 910.450 ---------- ---------- GBP16.47 1,756.522 ---------- ---------- GBP16.47 2,998.638 ---------- ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 5,665.610 GBP16.47 === ======================== ================================================ e) Date of the transaction 2017-04-18 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr R G Connor === ======================== ================================================ b) Position/status President, Global Manufacturing & Supply === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.47 1,367.102 ---------- ---------- GBP16.47 1,752.027 ---------- ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 3,119.129 GBP16.47 === ======================== ================================================ e) Date of the transaction 2017-04-18 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr L Debruyne === ======================== ================================================ b) Position/status President, Global Vaccines === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.47 349.698 ---------- ---------- GBP16.47 440.757 ---------- ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 790.455 GBP16.47 === ======================== ================================================ e) Date of the transaction 2017-04-18 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr S Dingemans === ======================== ================================================ b) Position/status Chief Financial Officer === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793
=== ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.47 2,973.255 ---------- ---------- GBP16.47 3,220.155 ---------- ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 6,193.410 GBP16.47 === ======================== ================================================ e) Date of the transaction 2017-04-18 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr N Hirons === ======================== ================================================ b) Position/status SVP, Global Ethics & Compliance === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.47 662.840 ---------- ---------- GBP16.47 722.300 ---------- ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 1,385.140 GBP16.47 === ======================== ================================================ e) Date of the transaction 2017-04-18 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr S A Hussain === ======================== ================================================ b) Position/status President, Global Pharmaceuticals === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.47 3,107.069 ---------- ---------- GBP16.47 3,502.071 ---------- ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 6,609.140 GBP16.47 === ======================== ================================================ e) Date of the transaction 2017-04-18 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mr D S Redfern === ======================== ================================================ b) Position/status Chief Strategy Officer === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.47 1,087.465
---------- ---------- GBP16.47 1,269.488 ---------- ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 2,356.953 GBP16.47 === ======================== ================================================ e) Date of the transaction 2017-04-18 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Ms C Thomas === ======================== ================================================ b) Position/status SVP, HR === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.47 1,449.959 ---------- ---------- GBP16.47 1,597.807 ---------- ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 3,047.766 GBP16.47 === ======================== ================================================ e) Date of the transaction 2017-04-18 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ============================================================================ a) Name Mr P C Thomson === ========================== ================================================ b) Position/status President, Global Affairs === ======================== ================================================== c) Initial notification/ Initial notification amendment === ========================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ============================================================================ a) Name GlaxoSmithKline plc === ========================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ========================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ============================================================================ a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ========================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ========================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.47 838.910 ---------- ---------- GBP16.47 919.292 ---------- ---------- === ========================== ================================================ d) Aggregated information Aggregated volume Price 1,758.202 GBP16.47 === ========================== ================================================ e) Date of the transaction 2017-04-18 === ========================== ================================================ f) Place of the n/a transaction === ========================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Dr P J T Vallance === ======================== ================================================ b) Position/status President, R&D === ======================== ================================================ c) Initial notification/ Initial notification amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.47 3,015.919 ---------- ---------- GBP16.47 3,720.939 ---------- ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 6,736.858 GBP16.47 === ======================== ================================================ e) Date of the transaction 2017-04-18 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================ 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================== a) Name Mrs V A Whyte === ======================== ================================================ b) Position/status Company Secretary === ======================== ================================================ c) Initial notification/ Initial notification
amendment === ======================== ================================================ 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================== a) Name GlaxoSmithKline plc === ======================== ================================================ b) LEI 5493000HZTVUYLO1D793 === ======================== ================================================ 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ================================================ b) Nature of the Increase in notional interest in Ordinary transaction Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan. === ======================== ================================================ c) Price(s) and Price(s) Volume(s) volume(s) ---------- ---------- GBP16.47 175.499 ---------- ---------- GBP16.47 185.700 ---------- ---------- === ======================== ================================================ d) Aggregated information Aggregated volume Price 361.199 GBP16.47 === ======================== ================================================ e) Date of the transaction 2017-04-18 === ======================== ================================================ f) Place of the n/a transaction === ======================== ================================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLFLFLDZFXBBZ
(END) Dow Jones Newswires
April 21, 2017 08:36 ET (12:36 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions